Tasca Therapeutics Launches with $52 Million Series A Financing to Develop Small Molecule Inhibitors for Multiple Oncology IndicationsProceeds from the financing to be utilized to complete proof of concept Phase 1/2 clinical study for lead candidate, CP-383

Tasca Therapeutics以5200万美元的A系列融资启动，以开发用于多种肿瘤学指标的小分子抑制剂，该融资过程将用于完成主要候选药物CP-383的概念验证1/2期临床研究

Financing co-led by Regeneron Ventures and Cure Ventures with participation by Invus Group

由Regeneron Ventures和Cure Ventures联合牵头，Invus Group参与融资

Praveen Tipirneni appointed chairman of the boardBOSTON, December 10, 2024-- Tasca Therapeutics Corp. (“Tasca”), a biotechnology company leveraging a unique drug discovery platform that identifies and maps novel lipid-binding pockets on proteins to develop new medicines to treat human diseases, today announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group.

2024年12月10日，Praveen Tipirneni被任命为董事会主席波士顿——Tasca Therapeutics Corp.（“Tasca”），一家利用独特的药物发现平台识别和绘制蛋白质上新的脂质结合口袋以开发治疗人类疾病的新药的生物技术公司，今天宣布了一项5200万美元的a系列融资，由Regeneron Ventures和Cure Ventures共同领导，Invus Group参与。

This funding will be used to advance Tasca’s novel drug discovery platform, progress its lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies, and to expand its drug candidate pipeline..

这笔资金将用于推进Tasca的新药发现平台，将其领先项目CP-383推进1/2期临床概念验证研究，并扩大其候选药物渠道。。

“We are excited to enter this next phase of company growth with financial support from such leading life science investors and the continued backing of our pioneering scientific co-founders - Xu Wu, Ph.D., David Fisher, M.D., Ph.D., and Duojia Pan, Ph.D.,” said Milenko Cicmil, co-founder and chief executive officer of Tasca.

Tasca联合创始人兼首席执行官米连科·西米利（MilenkoCicmil）表示：“我们很高兴能在这些领先的生命科学投资者的财政支持下，在我们开创性的科学联合创始人徐武（Xu Wu）博士、大卫·费舍尔（David Fisher）博士（David Fisher）博士（David Fisher）和潘多嘉（Duojia Pan）博士（Duojia Pan）的持续支持下，进入公司下一阶段的发展。”。

“Our first development candidate, CP-383, is a unique first-in-class molecule demonstrating excellent efficacy across multiple cancer types and we are looking forward to progressing it into the clinic.”.

“我们的第一个开发候选人CP-383是一种独特的一流分子，在多种癌症类型中表现出优异的疗效，我们期待着将其应用于临床。”。

Named after the Italian word for “pocket,” Tasca is harnessing the power of mass spectrometry-based proteomics, coupled with the use of proprietary reagents, to identify proteins that undergo a specific post-translational modification called auto-palmitoylation. The specific sites of auto-palmitoylation, once mapped and characterized, serve as unique binding sites for novel therapeutics that can be developed to modify the function of the target protein.

Tasca以意大利语“口袋”一词命名，利用基于质谱的蛋白质组学的力量，结合专有试剂的使用，来鉴定经过特定翻译后修饰的蛋白质，称为自动棕榈酰化。自动棕榈酰化的特定位点一旦被定位和表征，就可以作为新疗法的独特结合位点，可以开发新疗法来修饰靶蛋白的功能。

The auto-palmitoylated proteins Tasca identified represent a rich source of druggable targets across a range of therapeutic indications..

鉴定出的自动棕榈酰化蛋白Tasca代表了一系列治疗适应症中丰富的药物靶标来源。。

Tasca’s most advanced drug candidate, CP-383, is a first-in-class molecule that has demonstrated robust anti-cancer activity in both in vitro and in vivo studies across a broad range of human cancers, and will initially be evaluated in small cell lung cancer, colorectal cancer, head and neck cancer, and brain cancer patients..

Tasca最先进的候选药物CP-383是一流的分子，在多种人类癌症的体外和体内研究中均显示出强大的抗癌活性，最初将在小细胞肺癌，结直肠癌，头颈癌和脑癌患者中进行评估。。

Expert Executive Leadership Team

专家执行领导团队

Tasca’s executive leadership team brings decades of experience in drug discovery and development, as well as a successful history of launching and leading new biotechnology programs and start-ups. Tasca’s executives have held major roles at several big pharma companies, including Merck, AstraZeneca, Bristol Myers Squibb, and Novartis.

Tasca的执行领导团队在药物发现和开发方面拥有数十年的经验，以及启动和领导新生物技术项目和初创企业的成功历史。Tasca的高管曾在几家大型制药公司担任主要职务，包括默克（Merck）、阿斯利康（AstraZeneca）、百时美施贵宝（Bristol-Myers Squibb）和诺华（Novartis）。

Their deep understanding of oncology matched with drug development and business expertise will enable them to find creative solutions for challenges faced by early-stage biotechnology companies..

他们对肿瘤学的深刻理解与药物开发和商业专业知识相匹配，将使他们能够为早期生物技术公司面临的挑战找到创造性的解决方案。。

“I was immediately impressed by Tasca’s in vivo data, that combined with the amazing leadership that Milenko provides and backing of strong firms like Regeneron Ventures and Cure Ventures,” said Praveen Tipirneni, M.D., and chairman of the board. “I look forward to bringing my Morphic Therapeutic experience to the Tasca team.”.

董事会主席Praveen Tipirneni医学博士说：“Tasca的体内数据给我留下了深刻的印象，这些数据加上米连科提供的惊人领导力以及Regeneron Ventures和Cure Ventures等强大公司的支持。”。“我期待着将我的Morphic治疗经验带给Tasca团队。”。

Added Dave Fallace, co-founder and managing partner at Cure Ventures: “We founded Cure Ventures to help develop curative technologies and Tasca is expanding the boundaries of science with the potential of their platform. The prospect of being able to drug previously undruggable targets in oncology and potentially other indications differentiates Tasca from the competition.

Cure Ventures联合创始人兼管理合伙人戴夫·法拉斯（Dave Fallace）补充道：“我们成立了Cure Ventures，以帮助开发治疗技术，Tasca正在利用其平台的潜力扩大科学的边界。能够治疗肿瘤学和其他潜在适应症中以前无法治疗的目标的前景使Tasca与竞争对手有所不同。

We’re confident in their programs and look forward to supporting them as they advance their platform and pipeline.”.

我们对他们的计划充满信心，并期待着在他们推进平台和管道的过程中为他们提供支持。”。

About Tasca Therapeutics

关于Tasca Therapeutics

Tasca is a privately held biotechnology company focused on discovering and developing small molecule inhibitors of auto-palmitoylated target proteins important in cancer. The Company’s lead program, CP-383, is a first-in-class drug candidate, with promising preclinical activity against multiple cancer types.

Tasca是一家私营生物技术公司，专注于发现和开发对癌症重要的自体棕榈酰化靶蛋白的小分子抑制剂。该公司的领先项目CP-383是一流的候选药物，对多种癌症类型具有良好的临床前活性。

For more information, visit www.tascatx.com.Contact: .

有关更多信息，请访问www.tascatx.com.Contact：。。

Media Contact:

媒体联系人：

Rachel Ford Hutman

雷切尔·福特·赫特曼

Ford Hutman Media

福特哈特曼媒体

rachel@fordhutmanmedia.com

rachel@fordhutmanmedia.com

+1.301.801.5540

+1.301.801.5540